Clinical Trial Update: TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options [Phase 3]

View source ↗

Summary

Phase 3 study assessing safety of TMC114 (darunavir) boosted with low-dose ritonavir in experienced HIV-1 infected patients with limited or no treatment options…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Darunavir (darunavir)
• Ritonavir (Ritonavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infections | Phase 3 | Status: COMPLETED